结直肠癌肝转移肝切除围术期循环肿瘤DNA动态变化的前瞻性研究
该前瞻性研究纳入48例接受根治性肝切除的结直肠癌肝转移患者,评估围术期ctDNA动态与预后的关联。中位随访55个月,ctDNA术前术后均阳性者无复发生存期最差(中位6.0个月),而术前阳性术后转阴者预后显著改善(HR 0.24)。围术期ctDNA动态可识别高复发风险患者,或可指导治疗决策与术后监测。
要点
- 肝切除术前术后ctDNA均阳性者复发风险最高(中位RFS 6.0个月,P=0.001)
- 术前阳性术后转阴者较持续阳性者RFS和OS均显著改善(HR均为0.24)
- 组织体细胞突变与生存无显著关联,围术期ctDNA动态更具预后价值
核心结论
- 围术期ctDNA动态与结直肠癌肝转移肝切除患者生存相关,可识别高复发风险患者,或可指导治疗决策与术后监测。
研究设计与样本
- 前瞻性研究纳入48例2013-2017年接受术前化疗后根治性肝切除的结直肠癌肝转移患者,采用血浆-only检测分析肝切除前与术后配对ctDNA,中位随访55个月。
主要发现
- ctDNA术前术后均阳性14例(29%),术前阳性术后阴性19例(40%),均阴性11例(23%)。
- ctDNA+/+组中位RFS为6.0个月,ctDNA+/-组未达到,ctDNA-/-组为33.0个月(P=0.001)。
- 与ctDNA+/+相比,ctDNA+/-的RFS改善(HR 0.24,95%CI 0.1-0.58),OS亦改善(HR 0.24,95%CI 0.08-0.74)。
- 组织体细胞突变(TP53 54%、RAS 48%、SMAD4 10%、FBXW7 6%、BRAF 4%)与生存无显著关联。
- 校正术前化疗、同时性病变和≥2个肝转移灶后,ctDNA+/-(HR 0.21,95%CI 0.08-0.53)和ctDNA-/-(HR 0.21,95%CI 0.08-0.56)均独立关联RFS改善。
临床怎么用
- 对结直肠癌肝转移肝切除患者,可考虑围术期ctDNA动态检测以辅助复发风险分层。
- 术前ctDNA阳性而术后转阴者预后较好,持续阳性者需加强术后监测与治疗决策。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To evaluate the association of perioperative ctDNA dynamics on outcomes after hepatectomy for CLM. SUMMARY BACKGROUND DATA: Prognostication is imprecise for patients undergoing hepatectomy for CLM, and ctDNA is a promising biomarker. However, clinical implications of perioperative ctDNA dynamics are not well established. METHODS: Patients underwent curative-intent hepatectomy after preoperative chemotherapy for CLM (2013-2017) with paired prehepatectomy/postoperative ctDNA analyses via plasma-only assay. Positivity was determined using a proprietary variant classifier. Primary endpoint was recurrence-free survival (RFS). Median follow-up was 55 months. RESULTS: Forty-eight patients were included. ctDNA was detected before and after surgery (ctDNA+/+) in 14 (29%), before but not after surgery (ctDNA+/-) in 19 (40%), and not at all (ctDNA-/-) in 11 (23%). Adverse tissue somatic mutations were detected in TP53 (n = 26; 54%), RAS (n = 23; 48%), SMAD4 (n = 5; 10%), FBXW7 (n = 3; 6%), and BRAF (n = 2; 4%). ctDNA+/+ was associated with worse RFS (median: ctDNA+/+, 6.0 months; ctDNA+/-, not reached; ctDNA-/-, 33.0 months; P = 0.001). Compared to ctDNA+/+, ctDNA+/- was associated with improved RFS [hazard ratio (HR) 0.24 (95% confidence interval (CI) 0.1-0.58)] and overall survival [HR 0.24 (95% CI 0.08-0.74)]. Adverse somatic mutations were not associated with survival. After adjustment for prehepatectomy chemotherapy, synchronous disease, and ≥2 CLM, ctDNA+/- and ctDNA-/- were independently associated with improved RFS compared to ctDNA+/+ (ctDNA+/-: HR 0.21, 95% CI 0.08-0.53; ctDNA-/-: HR 0.21, 95% CI 0.08-0.56). CONCLUSIONS: Perioperative ctDNA dynamics are associated with survival, identify patients with high recurrence risk, and may be used to guide treatment decisions and surveillance after hepatectomy for patients with CLM.
引用
- Newhook TE, Overman MJ, Chun YS, et al. Prospective Study of Perioperative Circulating Tumor DNA Dynamics in Patients Undergoing Hepatectomy for Colorectal Liver Metastases. Ann Surg. 2022. PMID: 35797554. doi:10.1097/SLA.0000000000005461
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。